AxyS Pharmaceuticals Inc. published for the first time details of its Delta technology, which had been described previously as a structure-based drug design approach for finding specific potent protease inhibitors.

As published last week in Nature, the basis for Delta boils down to the use of zinc ions to generate inhibitors with a higher affinity and specificity for the active site of